{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:07:29Z","timestamp":1794604049305,"version":"4.9.1"},"reference-count":23,"publisher":"The Journal of Rheumatology","issue":"Suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)\u2013Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group\u2014comprising rheumatologists, dermatologists, methodologists, and patient research partners\u2014provided updates at the GRAPPA 2022 annual meeting on its work to evaluate composite outcome measures for PsA. Ten composite outcome measures were considered. Initial steps were to define the population, the purpose of use, and the proposed pros and cons of the 10 candidate composite instruments for PsA. Preliminary Delphi exercises within the working group and GRAPPA stakeholders confirmed high priority for evaluating minimal disease activity (MDA); moderate priority for Disease Activity in PsA (DAPSA), American College of Rheumatology (ACR) response criteria, Psoriatic Arthritis Disease Activity Score (PASDAS), Composite Psoriatic Disease Activity Index (CPDAI), 3 visual analog scale (VAS), and 4VAS; and low priority for Disease Activity Score in 28 joints (DAS28), Psoriatic Arthritis Responder Criteria (PsARC), and Routine Assessment of Patient Index Data 3 (RAPID3). Further appraisal of candidate composite instruments is ongoing.<\/jats:p>","DOI":"10.3899\/jrheum.2023-0530","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T12:20:25Z","timestamp":1688732425000},"page":"53-57","source":"Crossref","is-referenced-by-count":18,"title":["Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group"],"prefix":"10.3899","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8492-6342","authenticated-orcid":false,"given":"Ying-Ying","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5948-0000","authenticated-orcid":false,"given":"Maarten","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-8567","authenticated-orcid":false,"given":"Ana-Maria","family":"Orbai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6607-6070","authenticated-orcid":false,"given":"Oliver","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-9105","authenticated-orcid":false,"given":"Philip S.","family":"Helliwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5869-5157","authenticated-orcid":false,"given":"Niti","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6600-0631","authenticated-orcid":false,"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-2824","authenticated-orcid":false,"given":"Christine A.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-310X","authenticated-orcid":false,"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"2023110105251428000_50.Suppl_2.53.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210242"},{"key":"2023110105251428000_50.Suppl_2.53.2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.semarthrit.2021.08.011","article-title":"The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2","volume":"51","author":"Maxwell","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2023110105251428000_50.Suppl_2.53.3","unstructured":"U.S. Department of Health and Human Services, FDA, CDER, CBER . Multiple endpoints in clinical trials: guidance for industry. [Internet. Accessed June 8, 2023]. Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/Multiple-Endpoints-in-Clinical-Trials-Guidance-for-Industry.pdf"},{"key":"2023110105251428000_50.Suppl_2.53.4","unstructured":"Committee for Medicinal Products for Human Use (CHMP) . Guideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis. [Internet. Accessed June 8, 2023]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-rheumatoid-arthritis_en.pdf"},{"key":"2023110105251428000_50.Suppl_2.53.5","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.semarthrit.2021.11.001","article-title":"Composite outcomes at OMERACT: multi-outcome domains and composite outcome domains","volume":"51","author":"Wells","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2023110105251428000_50.Suppl_2.53.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110278"},{"key":"2023110105251428000_50.Suppl_2.53.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2023110105251428000_50.Suppl_2.53.8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002457"},{"key":"2023110105251428000_50.Suppl_2.53.9","doi-asserted-by":"crossref","first-page":"152134","DOI":"10.1016\/j.semarthrit.2022.152134","article-title":"Comparison of Disease Activity Index for Psoriatic Arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: a post hoc analysis of data from phase 3 tofacitinib studies","volume":"58","author":"Schneeberger","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2023110105251428000_50.Suppl_2.53.10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002366"},{"key":"2023110105251428000_50.Suppl_2.53.11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/rheumatology\/keac375","article-title":"Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis","volume":"62","author":"Coates","year":"2023","journal-title":"Rheumatology"},{"key":"2023110105251428000_50.Suppl_2.53.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205207"},{"key":"2023110105251428000_50.Suppl_2.53.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181077"},{"key":"2023110105251428000_50.Suppl_2.53.14","doi-asserted-by":"publisher","DOI":"10.5662\/wjm.v11.i4.116"},{"key":"2023110105251428000_50.Suppl_2.53.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.22552"},{"key":"2023110105251428000_50.Suppl_2.53.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2023110105251428000_50.Suppl_2.53.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122259"},{"key":"2023110105251428000_50.Suppl_2.53.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201341"},{"key":"2023110105251428000_50.Suppl_2.53.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.129379"},{"key":"2023110105251428000_50.Suppl_2.53.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201674"},{"key":"2023110105251428000_50.Suppl_2.53.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.49.11.916"},{"key":"2023110105251428000_50.Suppl_2.53.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391210"},{"key":"2023110105251428000_50.Suppl_2.53.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.008"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-0530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T12:30:27Z","timestamp":1698841827000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-0530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":23,"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2023,11,1]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.3899\/jrheum.2023-0530"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-0530","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}